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MYCN is a well-known oncogene over-expressed in different humanmalignancies including
neuroblastoma (NB), rhabdomyosarcoma, medulloblastoma, astrocytoma, Wilms’ tumor,
and small cell lung cancer. In the case of NB, MYCN ampliﬁcation is an established
biomarker of poor-prognosis. MYCN belongs to a family of transcription factors (the most
important of which is C-MYC) that show a high degree of homology. Down-regulation
of MYC protein expression leads to tumor regression in animal models, indicating that
MYC proteins represent interesting therapeutic targets. Pre-requisites for a candidate
tumor-associated antigen (TAA) to be targeted by immunotherapeutic approaches are the
following, (i) expression should be tumor-restricted, (ii) the putative TAA should be up-
regulated in cancer cells, and (iii) protein should be processed into immunogenic peptides
capable of associating to major histocompatibility complex molecules with high afﬁnity.
Indeed, the MYCN protein is not expressed in human adult tissues and up-regulated vari-
ably in NB cells, andMYCNpeptides capable of associating toHLA-A1 or HLA-A2molecules
with high afﬁnity have been identiﬁed. Thus the MYCN protein qualiﬁes as putative TAA
in NB. Additional issues that determine the feasibility of targeting a putative TAA with
cytotoxic T lymphocytes (CTLs) and will be here discussed are the following, (i) the inade-
quacy of tumor cells per se to act as antigen-presenting cells witnessed, in the case of NB
cells, by the low to absent expression of HLA class I molecules, the lack of co-stimulatory
molecules and multiple defects in the HLA class I related antigen processing machin-
ery, and (ii) the immune evasion mechanisms operated by cancer cells to fool the host
immune system, such as up-regulation of soluble immunosuppressive molecules (e.g.,
soluble MICA and HLA-G in the case of NB) or generation of immunosuppressive cells in
the tumor microenvironment. A ﬁnal issue that deserves consideration is the strategy used
to generate CTL.
Keywords: MYCN oncoprotein, neuroblastoma, tumor antigen, cytotoxicT cells, immunotherapy
INTRODUCTION
MYCN is a well-known oncogene over-expressed in differ-
ent human malignancies including neuroblastoma (NB), rhab-
domyosarcoma, medulloblastoma, Wilms’ tumor, and small cell
lung cancer (Lee et al., 1984; Garson et al., 1985; Nisen et al.,
1986; Wong et al., 1986; Williamson et al., 2005). In the case of
NB, MYCN ampliﬁcation is an established prognostic biomarker
that helps stratify patients in different risk categories (Brodeur
et al., 1984).
MYCN belongs to a family of transcription factors (the most
important of which is C-MYC) with high degree of struc-
tural homology (Malynn et al., 2000). Down-regulation of MYC
protein expression in different animal models of human malig-
nancies leads to tumor regression, indicating that MYC proteins
represent interesting therapeutic targets (Pelengaris et al., 1999;
Morgenstern and Anderson, 2006).
Transgenic expression of the humanMYCN gene inmice under
the control of the tyrosine hydroxylase (TH) promoter is followed
by the spontaneous development of MYCN-ampliﬁed human NB
in the adrenal gland, that mimics that natural history of primary
NB (Weiss et al., 1997). This innovative model has allowed to
broaden knowledge on NB pathogenesis and design therapeutic
strategies aimed at inhibiting expression of MYCN protein and
consequently dampening tumor growth. Such strategies are dis-
cussed in detail in other articles of this issue of Frontiers in
Oncology and are beyond the scope of this review.
The immune system has evolved into two major arms making
use of innate and adaptive mechanisms, respectively, in order to
cope with pathogens. The adaptive immune system is composed
of B and T lymphocytes that interact speciﬁcally with antigens
through two different sets of antigen receptors, i.e., the B cell
receptor (BCR) and the T cell receptor (TCR), respectively (Abbas
et al., 2011). At variance with the BCR that recognizes native pro-
tein antigens, the TCR binds to small peptides generated following
antigen processing by antigen-presenting cells (APCs). These pep-
tides associate with nascent major histocompatibility complex
(MHC) molecules and are presented to the TCR on T cells (Abbas
et al., 2011). Antigen-derived peptides must ﬁt in size within small
pockets present in T cell-associated MHC class I or II molecules.
Peptide binding to TCR (ﬁrst signal) causes T cell activation only
when co-stimulatory molecules present on APCs are engaged by
their ligands on T cells (second signal). In the absence of the lat-
ter interactions, T cells that have bound antigen-derived peptides
undergo apoptosis or anergy (Abbas et al., 2011).
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Tumor growth is assisted by different immune evasion mech-
anisms that frustrate the attempts of the host immune system to
eliminate cancer cells (Schreiber et al., 2011). Major goals of tumor
immunology are to unravel such mechanisms and to develop
immunotherapeutic approaches leading to tumor regression.
Based upon this background, we discuss here MYCN as
potential target for NB immunotherapy.
THE MYCN PROTEIN AS PUTATIVE TUMOR-ASSOCIATED
ANTIGEN
Malignant cells express antigens sharedwith their normal counter-
parts and antigens that are tumor-restricted since their expression
is reactivated in cancer cells only, e.g., embryonal antigens. In
order to hit selectively neoplastic cells, immunotherapy must tar-
get tumor-associated antigens (TAAs) present almost exclusively
on tumor cells. A good example in this respect is represented by
anti-GD2 monoclonal antibodies used for therapy of high risk
NB patients. GD2 is a ganglioside expressed in the central ner-
vous system that shows a very limited expression in the peripheral
tissues and is therefore amenable to be targeted for NB treat-
ment (Seeger, 2011). Anti-TAA monoclonal antibodies kill tumor
cells by promoting antibody-dependent cell cytotoxicity, operated
predominantly by NK cells andmacrophages that bind the Fc por-
tion of cancer cell-coating IgG through speciﬁc surface receptors.
An additional mechanism involved in the anti-tumor activity of
anti-TAA antibodies is complement-dependent cell cytotoxicity.
A second pre-requisite for a candidate TAA is its expression
at high level on cancer cells which reinforces interaction between
BCR or TCR and the putative TAA.
Finally, T cell-targeted TAA must be processed into immuno-
genic peptides capable of associating with high afﬁnity to MHC
molecules, thus allowing strong binding of the MHC–peptide
complex to TCR. Selection of the best peptides for T cell-based
immunotherapy is facilitated by bioinformatics tools that predict
the peptide afﬁnity for MHC molecules.
During murine development, MYCN is expressed in different
tissues such as the heart, the neural tube, and the limb buds. At
birth, MYCN expression is detected in brain, intestine, kidney,
heart, and lung, but is lost in the ﬁrst weeks of life (Jakobovits
et al., 1985; Zimmerman et al., 1986, 1990; Semsei et al., 1989).
Recently, Anderson and colleagues have provided further evidence
that MYCN mRNA is virtually undetectable in most adult human
tissues, at variance with rhabdomyosarcoma and NB cell lines that
over-express this oncogene (Himoudi et al., 2008). Thus, MYCN
behaves as an embryonal TAAwhose expression is down-regulated
shortly after birth and up-regulated in cancer cells of neuroecto-
dermal origin, including NB, through different mechanisms such
as gene ampliﬁcation.
Two MYCN-derived peptides capable of eliciting cytotoxic T
lymphocyte (CTL) responses against NB cells have been identi-
ﬁed (Sarkar and Nuchtern, 2000; Himoudi et al., 2008). Nuchtern
and colleagues selected on the ground of its long-life and syn-
thesized the nine amino acid MYCN-derived S69K peptide that
contains an HLA-A1 binding motif. S69K was then used to gener-
ate CTL from peripheral bloodmononuclear cells of an HLA-A1+
normal donor and an HLA-A1+ NB patient carrying a MYCN-
ampliﬁed tumor (Sarkar and Nuchtern, 2000). Recognition of
tumor cells by these CTL was found to depend on MYCN ampliﬁ-
cation andHLA speciﬁcity, since CTL lysed onlyMYCN-ampliﬁed
primary NB cells that expressed HLA-A1. The immunopheno-
type of S69K peptide-stimulated CTL was found to be CD3+,
CD8+. Since NB cells display very low expression of HLA class
I molecules (see below), Nuchtern and colleagues investigated
whether incubation of tumor cells with interferon-γ (IFN-γ),
that up-regulates HLA class I expression, improved the rate of
lysis operated by S69K peptide-speciﬁc CTL. These experiments
showed that IFN-γ pre-treated NB cells were killed twice more
efﬁciently than untreated NB cells, but pre-incubation of tumor
cells with the cytokine was dispensable for lysis to occur. Thus, low
level expression of HLA class I onNB cells does not preclude recog-
nition of at least a subset of them by S69K peptide-speciﬁc CTL
(Sarkar and Nuchtern, 2000).
Using a bioinformatics approach, Anderson and colleagues
identiﬁed in the MYCN sequence the 10 amino acid VIL peptide,
predicted to bind HLA-A2 (Himoudi et al., 2008). This peptide
showed favorable binding activity and the VIL epitope was not
detected in any other human protein sequence including C-MYC.
VIL-speciﬁc CTL were generated from two normal donors and
a child with advanced MYCN-ampliﬁed NB using the following
protocol. First autologous dendritic cells (DCs) and then autolo-
gous B cells and irradiated feeder cells were pulsedwith the peptide
in the presence of IL-2 and IL-7 for the ﬁrst 2 weeks of culture.
Peptide pulsing was repeated in the second 2 weeks using a differ-
ent cytokine milieu, i.e., IL-2 and IL-12. Anderson and colleagues
showed that VIL-speciﬁc CTL lysed speciﬁcally MYCN-ampliﬁed
target cells in an HLA-A2-restricted manner. Furthermore, VIL-
speciﬁc CTL released IFN-γ upon incubation with the same target
cells, suggesting that this cytokine might improve the efﬁciency of
NB cell killing by up-regulating HLA class I expression onNB cells
(Himoudi et al., 2008).
Taken together, these results indicate that (i) MYCN is
a good target for T cell mediated anti-NB immunotherapy,
although this potential approach is limited to patients carrying
MYCN-ampliﬁed tumors, (ii) theHLA-A1 andHLA-A2-restricted
MYCN-derived peptides identiﬁed by the groups of Nuchtern
and Anderson, respectively, can be used to treat more than half
Caucasian patients due to the widespread distribution of these
alleles in the general population, and (iii) HLA class I expres-
sion on NB cells is low, but this does not preclude lysis of a
subpopulation of MYCN-ampliﬁed NB cells by MYCN peptide-
speciﬁc CTL.
IMMUNE EVASION MECHANISMS OPERATED BY
NEUROBLASTOMA TUMORS
As anticipated, tumor growth is facilitated by cancer cell-driven
immunosuppressive mechanisms. In the tumor microenviron-
ment, interactions between malignant cells and stromal cells
mediated by soluble factors and direct cell to cell contact mod-
ulate macrophages, DCs, NK cells, cytotoxic, and helper T
lymphocytes toward a tolerogenic phenotype while expanding
immunosuppressive cell populations such as T regulatory cells
and myeloid-derived suppressor cells (Schreiber et al., 2011). In
this respect, it has been shown that cytokines as IL-6, IL-10,
and TGFβ1 are over-expressed in poor-prognosis NB cases, and
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that IL-6 promotes NB growth and metastasis through different
mechanisms (Seeger, 2011).
In the last 10 yearswe have contributed to elucidate the immune
evasion mechanisms adopted by NB cells to escape the control
of the host immune system. These studies have highlighted (i)
the release of soluble molecules suppressing anti-tumor immune
reactivity, such as the stress inducible NKG2D ligand MICA
(Raffaghello et al., 2004) and the HLA class Ib molecule HLA-
G (Morandi et al., 2007) and (ii) NB cell defects in the expression
of a few components of the HLA class I related antigen processing
machinery (APM; Raffaghello et al., 2005). We will focus on the
latter issue since it is closely related to the topic of this article.
Tumor-associated antigens are endogenous proteins processed
andpresented toCD8+ T cells in the context ofMHCclass I (MHC
I) antigens (HLAclass I inhumans). Inbrief,MHCIpeptide gener-
ation starts with polypeptide degradation by the proteasome in the
cytosol. Peptides generated by proteasomal digestion subsequently
undergo structural modiﬁcations operated by different peptidases
and bind to the transporter of antigen processing (TAP), a het-
erodimer composed of two different subunits named TAP1 and
TAP2. TAP-bound peptides are translocated into the endoplas-
mic reticulum or the Golgi where they are further trimmed by
aminopeptidases. Peptides of appropriate length (8–11 mers) that
are able to bind MHC I allelic products expressed by the cell are
inserted into MHC I proteins, formed in humans by the asso-
ciation of HLA class I heavy chain (HC) and β2-microglobulin
(β2m), and are exported to the cell surface. Peptide insertion in
MHC Imolecules is driven by a loading complex that includes dif-
ferent chaperons such as tapasin, calnexin, calreticulin, and Erp-57
(Tanaka and Kasahara, 1998; De Verteuil et al., 2012).
All eukaryotic cells possess constitutive proteasomes with a 20S
hollow proteolytic core providing a cavity open at both ends in
which proteins are degraded. The 20S proteasome is composed of
14 different subunits organized in a barrel-shaped complex with
the stoichiometry α7β7β7α7. Three subunits of the inner ring,
i.e., β1, β2, and β5 are directly involved in proteolytic cleavage.
In cells exposed to IFN-γ, these latter subunits are replaced by
LMP2 for β1, MECL1 (or LMP10) for β2 and LMP7 for β5 to
give rise to the 26S immunoproteasome, which generates more
immunogenic peptides from digested polypeptides. It is of note
that constitutive expression of the immunoproteasome is detected
in some cell types, such as for exampleDCs, that represent themost
potent professionalAPCs. Proteasomal subunits, both constitutive
and IFN-γ induced, the TAP complex and the chaperons that assist
in peptide loading onto MHC I are collectively referred to APM
(Tanaka and Kasahara, 1998; De Verteuil et al., 2012).
We investigated APM expression in human NB cells from both
primary tumors and continuous cell lines since APM abnormal-
ities, that have been identiﬁed in different tumor types, cause
defects in peptide generation, translocation, and loading onto
β2m–HLAHCcomplexes. Therefore, these complexes are retained
in the endoplasmic reticulum, are degraded by housekeeping pro-
teasomes to a larger extent and are unstable. IFN-γ treatment
of tumor cells usually restores peptide supply to β2m-HLA HC
complexes by up-regulating expression of APM components and
reverses HLA class I down-regulation, that is particularly evident
in NB cells (Seliger et al., 2000).
Immunohistochemical staining of a series of stroma-poor NB
tumors showed that LMP7, TAP2, β2m, and β2m-free HC, as well
as HLA class I and II molecules, were never expressed in tumor
cells. Pediatric adrenal medulla, tested as normal counterpart of
NB cells, expressed all theseAPMcomponents at variable intensity,
but tested negative for HLA class I and II. These results indicated
that absence of tapasin, TAP2, β2m, and β2m-free HC in primary
NB lesions was related to malignant transformation (Raffaghello
et al., 2005).
Flow cytometric analysis of a panel of NB cell lines showed that
the β1 constitutive proteasomal subunit, LMP2, LMP7, LMP10,
TAP1, and Erp-57 were virtually undetectable under basal con-
ditions (Raffaghello et al., 2005). Differences in APM component
expression detected in primaryNB cells vsNB cell lines (such as for
example LMP10 expression in the latter but not the former cells,
and Erp57 expression in the former but not the latter cells) may
be related to the different sensitivity of immunohistochemistry vs
ﬂow cytometry and/or to changes acquired by primary NB cells
during their transformation in immortal cell lines or later on due
to adaption to culture conditions.
Incubation of NB cell lines with IFN-γ caused up-regulation of
LMP2, tapasin, β2m, and β2m-free HC, as well as of surface HLA
class I. Functional experiments showed that lysis of IFN-γ treated
HLA class I negative NB cell lines by NK cells matched for HLA
class ligands of killer inhibitory receptors (KIR) was signiﬁcantly
reduced. In contrast, such reduction was not observed when the
same cell lines that had been pre-treated with IFN-γ were incu-
bated with activatedNK cells from healthy donorsmismatched for
KIR HLA class I ligands (Raffaghello et al., 2005).
In essence, these experiments demonstrated that (i) NB cells
display different defects inAPMcomponent expression and in sur-
face HLA class I expression that may contribute to altered peptide
generation and loading ontoHLA class Imolecules, (ii) incubation
of NBcellswith IFN-γup-regulates the expressionof selectedAPM
components and of surfaceHLA class Imolecules. This latter ﬁnd-
ing may represent a double-edge sword since on one hand IFN-γ
induced changes in NB cells that can improve their recognition
and lysis by TAA-speciﬁc CTL, but on the other hand can reduce
sensitivity of tumor cells to NK cell mediated lysis. Such consider-
ations must be kept in mind when designing immunotherapeutic
strategies aimed at promoting elimination of NB cells through
cytotoxic effector mechanisms operated by the host immune
system.
MYCN IS AMPLIFIED NOT ONLY IN BONA FIDE NB CELLS
BUT ALSO IN NB CELLS DISGUISED AS ENDOTHELIAL CELLS
Previous studies have demonstrated that tumor cells can line chan-
nels mimicking endothelial vessels. This phenomenon has been
denominated “vascular mimicry” and reported in various tumor
types including melanoma, renal carcinoma, B cell non-Hodgkin
lymphomas, and ﬁbrosarcoma (Hendrix et al., 2003).
We have recently investigated vascular mimicry in NB and
the underlying mechanisms. To detect tumor-derived endothelial
cells (TECs) in NB microenvironment we have used a combina-
tion of ﬂuorescent in situ hybridization (FISH) for MYCN and
immunoﬂuorescence for endothelial cell marker, mainly CD31
(Pezzolo et al., 2007, 2011).
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Using this approach, we have identiﬁed CD31+ cells carrying
MYCN ampliﬁcation in one-third of MYCN-ampliﬁed primary
NB tested and in tumors formed by MYCN-ampliﬁed human NB
cell lines in immunodeﬁcient mice (Figures 1A,B). These TEC
lined functional endothelial micro-vessels containing red blood
cells in their lumen (Figure 1B) and coated by α-smooth muscle
actin (SMA)+ pericytes that never displayed MYCN ampliﬁca-
tion and were therefore of host origin (Figure 1; Pezzolo et al.,
2007). An interesting feature of TEC was the co-expression of
mature endothelial cell markers [CD31, CD105, von Willebrand
factor, prostate-speciﬁc membrane antigen (PSMA), HLA class I]
together with neuroblastic markers such as GD2, CD56, CD57,
and NB84 (Pezzolo et al., 2011).
In these studies, we have identiﬁed a small subpopulation of NB
cells with perivascular location that express the Oct-4 transcrip-
tion factor, together with the extracellular matrix protein tenascin
C (TNC) on the cell surface. In vitro and in vivo experiments
demonstrated that these Oct-4+, TNC+ NB cells were endowed
with plasticity since they (i) co-expressed “stem cell” markers as
SOX-2 andWnt and formed neurospheres in culture under appro-
priate conditions, (ii) differentiated in vitro into endothelial-like
cells expressing vascular endothelial (VE)-cadherin and, in part,
CD31 following 2-week culture in the presence of VE growth fac-
tor (VEGF) and basic ﬁbroblast growth factor (bFGF), and (iii)
formed tumors in vivo that contained MYCN-ampliﬁed TEC,
whereas Oct-4−, TNC− NB cells gave rise to tumors devoid of
TEC (Pezzolo et al., 2011).
All of the above led to the conclusion that Oct-4+, TNC+
NB cells were progenitor cells that served as reservoir of TEC.
The implications of the existence of MYCN-ampliﬁed TEC are
that these cancer cells disguised as endothelial cells are genetically
unstable and involved in chemoresistance and tumor progres-
sion. Although in our studies we investigated MYCN ampliﬁ-
cation but not MYCN protein expression, it is well-known that
MYCN-ampliﬁed tumor usually over-express the correspond-
ing protein. Thus, targeting of these TEC with MYCN directed
immunotherapy may provide an additional beneﬁt to the patient.
PRACTICAL APPROACHES TO MYCN-TARGETED T CELL
IMMUNOTHERAPY
A ﬁnal issue that must be discussed is how MYCN-targeted T cell
immunotherapy can be accomplished and what approach has the
best chances of being successful.
MYCN-speciﬁc T cells can be generated ex vivo starting from
patient peripheral blood mononuclear cells, as exempliﬁed by
the experiments from the Nuchtern’s and Anderson’s groups,
expanded and reinfused into the patient (adoptive immunother-
apy; Sarkar and Nuchtern, 2000; Himoudi et al., 2008). Alterna-
tively, the patient immune system can be stimulated to generate
MYCN-speciﬁc endogenous CD8+ T cells.
Myeloid DCs can be generated by culture of patient peripheral
blood monocytes in the presence of cytokines as GM-CSF, IL-4,
TNF, or IFN-α, pulsed with MYCN peptide and incubated with
patient T cells in order to expand MYCN-speciﬁc CTL to be rein-
fused in the patient. This is one of the most popular approaches
to cancer immunotherapy due the potent APC function of DCs
(Jain, 2010).
A second approach to adoptive immunotherapy is transfec-
tion of patient DC with adeno-associated viral vectors, lentiviral
vectors or tumor mRNA in order to induce expression of TAA
in these APC and promote generation of TAA-speciﬁc CTL
(Jain, 2010). A few years ago, we conducted a study in which
DC generated from monocytes of NB patients or age-matched
healthy donors were transfected with mRNA from four pooled
NB cell lines and co-cultured with autologous CD8+ T lym-
phocytes (Morandi et al., 2006). Expanded CTL produced IFN-γ
upon incubation with HLA-matched NB cell lines and lysed in
HLA-restricted manner the same cell line, but not autologous T
cell blasts. CTL from normal subjects recognized only peptides
from anaplastic lymphoma-associated kinase (ALK) and prefer-
entially expressed antigen of melanoma (PRAME). CTL from NB
patients reacted not only to ALK and PRAME peptides but also
to peptides from survivin, telomerase, and TH (Morandi et al.,
2006). Reactivity of patient or normal CTL to MYCN peptide
was not investigated in this study, but it is conceivable that
FIGURE 1 | Neuroblastoma-derived endothelial micro-vessels. (A)
Immunoﬂuorescence and ﬂuorescent in situ hybridization analysis of NB
tumor section highlights CD31+ endothelial micro-vessel (green) carrying
MYCN ampliﬁcation (multiple red signals). (B)Two RBCs are in the open
lumen of the NB-derived endothelial micro-vessel. Nuclei are stained with
DAPI (blue), ×100.
Frontiers in Oncology | Cancer Molecular Targets andTherapeutics November 2012 | Volume 2 | Article 174 | 4
“fonc-02-00174” — 2012/11/14 — 18:08 — page 5 — #5
Pistoia et al. MYCN oncoprotein as immunotherapeutic target in neuroblastoma
MYCNpeptide-speciﬁc CTL can be generated using tumormRNA
DC transfection from NB patients carrying MYCN-ampliﬁed
tumors.
The third and most promising approach of adoptive immuno-
therapy of cancer rests upon the administration to patients of
chimeric antigen receptor (CAR)-engineered lymphocytes. CARs
usually combine the antigen binding of a monoclonal antibody
with the signaling machinery of a T cell. Further modiﬁca-
tion of last generation CAR include the addition of stimulatory
domains that increase activation of CAR-bearing T cells. Gene
transfer procedures such as transduction with retrovirus and
transfection with plasmids are used to graft CAR into T cells.
An advantage of CAR-engineered T lymphocytes is that they kill
tumor cells expressing target antigens on the cell surface in a
HLA-independent manner. Survival of CAR-engineered T cells
after adoptive transfer is improved by lymphodepletion before
and provision of T cell growth factor after infusion (Ramos and
Dotti, 2011).
Chimeric antigen receptor-engineered T cells expressing a
chimeric anti-GD2 antibody on the cell surface have been gen-
erated and administered to NB patients in the frame of a phase I
study, in which EBV-speciﬁc T cells were grafted with the chimeric
construct and periodically restimulated with the speciﬁc antigen
in order to promote their long-term survival. Complete remission
was achieved in 3/11 patients with active disease and persistence
in vivo of GD2 carrying CAR beyond 6 weeks was found to be
associated with better clinical response (Pule et al., 2008; Louis
et al., 2011).
In principle, this very same strategy can be applied to generate
TAA-speciﬁc in general, and MYCN peptide-speciﬁc in partic-
ular, CD8+ T cells that will be subsequently grafted with the
chimeric anti-GD2 antibody and infused in NB patients carrying
MYCN-ampliﬁed tumors.
Stimulation of the patient immune system to generate endoge-
nous MYCN-speciﬁc CTL may be achieved in two ways, (i)
administration of TAA peptide and (ii) vaccination with plasmid
carrying DNA sequences encoding the target TAA.
Peptide vaccination in cancer cells is feasible and displays a
favorable toxicity proﬁle, but patient immunization is achieved
only in a half of them. Different approaches have been recently
developed to induce stronger peptide-driven immune-mediated
control of tumor growth, with special emphasis onmulti-peptide-
based cancer vaccines. This latter approach presents numerous
advantages, such as (i) the possibility of overcoming tumor hetero-
geneity and selection of antigen-negative clones that have escaped
immune responses directed to a single peptide, and (ii) the com-
bination of HLA class I and class II restricted epitopes, thus
triggering CD4+- and CD8+-mediated recognition of cancer cells
(Jain, 2010; Perez et al., 2010).
Lode and colleagues have presented an abstract at the Advance
in Neuroblastoma Research 2012 meeting reporting on the devel-
opment of a MYCN-DNA (pMDV1) vaccine based on epitopes
encoding for three peptides from the MYCN protein sequence
with high afﬁnity to MHC I. This vaccine was tested in a novel
syngeneic MYCN over-expressing NXS2 mouse model. MYCN-
DNAvaccinationwas performed before challengewith tumor cells
and resulted in reduction of primary tumor growth as well as in
antigen-speciﬁc target cell killing (Stermann et al., 2012). These
preliminary ﬁndings may provide a platform for further clinical
development.
CONCLUSION
This review article provides evidence for MYCN protein as poten-
tial immunotherapeutic target in NB along different experimental
strategies that have been discussed in detail. The time of testing
such strategies in the clinical setting has come of age.
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